To test this hypothesis, tissue samples from 86 GC patients treated with first-line chemotherapy, either in prospective phase II trials or in routine clinical practice [27–30], were retrospectively evaluated by immunohistochemistry (IHC) for assessing the expression of YAP and TAZ. The gene discussed is WWTR1; the disease is gastric cancer.